UK pharma major GSK (LSE: GSK) has launched a lawsuit against Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).
The suit accuses the companies of breaching GSK mRNA vaccine technology patents in their development of the Comirnaty vaccine for COVID-19. The jab swiftly became a top-selling pharma product to help the world to move on from the pandemic, earning Pfizer $43 billion in global revenue in one year alone.
GSK claims that the research in question was conducted by Novartis (NOVN: VX) scientists. Under the leadership of vaccinologist Christian Mandl, their work focused on developing mRNA vaccines. The London-based company acquired rights to the technology in 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze